RT Journal Article
SR Electronic
T1 Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 730
OP 732
DO 10.1136/ard.2009.108456
VO 69
IS 4
A1 L Damjanovska
A1 M M Thabet
A1 E W N Levarth
A1 G Stoeken-Rijsbergen
A1 E I van der Voort
A1 R E M Toes
A1 T W J Huizinga
A1 A H M van der Helm-van Mil
YR 2010
UL http://ard.bmj.com/content/69/4/730.abstract
AB Objectives To evaluates the diagnostic performance of the anti-CCP2, anti-CCP3 and anti-mutated citrullinated vimentin (anti-MCV) tests in differentiating rheumatoid arthritis (RA) from other forms of arthritis in a clinical setting of early arthritis. Methods In 917 patients with recent-onset arthritis (566 RA, 351 other diseases) and in 99 healthy controls the anti-MCV, anti-CCP2 and anti- CCP3.1 tests were performed and the test characteristics compared. Results Comparison of the tests for differentiating RA from other causes of arthritis showed a lower specificity for anti-MCV (82.9%) than for anti-CCP2 (93.4%) and anti-CCP3.1 (90.0%). Similarly, the positive likelihood ratio for anti-MCV was also lower (3.6, compared with 8.7, 5.8 for anti-CCP2 and anti-CCP3.1). The anti-MCV test had a higher sensitivity (62% vs 56.9% and 58.1%, respectively). In psoriatic arthritis, spondyloarthropathy and other arthritis anti-MCV antibodies had a prevalence of 15.2%, 13.9% and 19.4%. Conclusion The diagnostic performance of the anti-MCV test in the differential diagnosis of early arthritis is lower than that of the anti-CCP tests.